Table 5.
Study Quality
| Reference | Year | Country | Study Design | Jadad Scale | Study Quality |
|---|---|---|---|---|---|
| Studies of Antidepressants for Prevention of PSD | |||||
| Niedermaier27 | 2004 | Germany | RCT | 2 | Poor |
| Tsai28 | 2011 | Taiwan | RCT | 4 | High |
| Almeida30 | 2006 | Australia | RCT | N/A | N/A |
| Rasmussen31 | 2003 | Denmark | RCT | 3 | High |
| Kim32 | 2017 | South Korea | RCT | 5 | High |
| Palomäki33 | 1999 | Finland | RCT | 4 | High |
| FOCUS Trial Collaboration34 | 2019 | UK | RCT | 5 | High |
| Zhang35 | 2013 | China | RCT | 2 | Poor |
| Cao36 | 2020 | China | RCT | 2 | Poor |
| AFFINITY Trial Collaboration29 | 2020 | Australia, New Zealand, Vietnam | RCT | 5 | High |
| EFFECTS Trial Collaboration37 | 2020 | Sweden | RCT | 3 | High |
| Studies of Non-Pharmacological Approaches for Prevention of PSD | |||||
| Zhang38 | 2019 | China | RCT | 3 | High |
| Lai39 | 2006 | USA | RCT | 3 | High |
| Jönsson46 | 2014 | Sweden | RCT | 3 | High |
| Boter47 | 2004 | Netherlands | RCT | 3 | High |
| Rochette48 | 2013 | Canada | RCT | 2 | Poor |
| Joubert49 | 2008 | Australia | RCT | 2 | Poor |
| Sajatovic50 | 2018 | USA | RCT | 2 | Poor |
| Gillham51 | 2010 | UK | RCT | 3 | High |
| Ihle-Hansen52 | 2019 | Norway | RCT | 1 | Poor |
| Cheng53 | 2018 | China | RCT | 3 | High |
| Hackett40 | 2013 | Australia | RCT | 3 | High |
| Faulkner41 | 2015 | New Zealand | RCT | 3 | High |
| Ihle-Hansen42 | 2014 | Norway | RCT | 3 | High |
| Kang43 | 2009 | South Korea | RCT | 2 | Poor |
| Kirk44 | 2014 | UK | RCT | 3 | High |
| Davis45 | 2004 | USA | RCT | 2 | Poor |
| Studies of Multimodal Strategies for Prevention of PSD | |||||
| Robinson54 | 2008 | USA | RCT | 5 | High |
| Hoffmann55 | 2015 | Australia | RCT | 3 | High |
| Mikami56 | 2011 | USA | RCT (follow-up) | N/A | N/A |
| Hill57 | 2019 | UK | RCT | 3 | High |
| Narushima58 | 2002 | USA | RCT | 4 | High |
Abbreviation: RCT, randomized controlled trial.